Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance.

Whitacre DC, Peters CJ, Sureau C, Nio K, Li F, Su L, Jones JE, Isogawa M, Sallberg M, Frelin L, Peterson DL, Milich DR.

Hum Vaccin Immunother. 2019 Dec 6:1-18. doi: 10.1080/21645515.2019.1689745. [Epub ahead of print]

PMID:
31809638
2.

Is the function of the HBeAg really unknown?

Milich DR.

Hum Vaccin Immunother. 2019;15(9):2187-2191. doi: 10.1080/21645515.2019.1607132. Epub 2019 May 9.

3.

The Concept of Immune Tolerance in Chronic Hepatitis B Virus Infection Is Alive and Well.

Milich DR.

Gastroenterology. 2016 Nov;151(5):801-804. doi: 10.1053/j.gastro.2016.09.037. Epub 2016 Oct 1. No abstract available.

PMID:
27702559
4.

P. falciparum and P. vivax Epitope-Focused VLPs Elicit Sterile Immunity to Blood Stage Infections.

Whitacre DC, Espinosa DA, Peters CJ, Jones JE, Tucker AE, Peterson DL, Zavala FP, Milich DR.

PLoS One. 2015 May 1;10(5):e0124856. doi: 10.1371/journal.pone.0124856. eCollection 2015.

5.

Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge.

Schickli JH, Whitacre DC, Tang RS, Kaur J, Lawlor H, Peters CJ, Jones JE, Peterson DL, McCarthy MP, Van Nest G, Milich DR.

J Clin Invest. 2015 Apr;125(4):1637-47. doi: 10.1172/JCI78450. Epub 2015 Mar 9.

6.

Functional aspects of intrahepatic hepatitis B virus-specific T cells induced by therapeutic DNA vaccination.

Brass A, Frelin L, Milich DR, Sällberg M, Ahlén G.

Mol Ther. 2015 Mar;23(3):578-90. doi: 10.1038/mt.2014.233. Epub 2014 Dec 10.

7.

Identification of a unique double-negative regulatory T-cell population.

Lee BO, Jones JE, Peters CJ, Whitacre D, Frelin L, Hughes J, Kim WK, Milich DR.

Immunology. 2011 Dec;134(4):434-47. doi: 10.1111/j.1365-2567.2011.03502.x.

8.

Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3/4A-specific T cells during therapeutic vaccination.

Chen A, Ahlén G, Brenndörfer ED, Brass A, Holmström F, Chen M, Söderholm J, Milich DR, Frelin L, Sällberg M.

J Immunol. 2011 May 1;186(9):5107-18. doi: 10.4049/jimmunol.1001790. Epub 2011 Mar 23.

9.

Improving on the ability of endogenous hepatitis B core antigen to prime cytotoxic T lymphocytes.

Nyström J, Chen A, Frelin L, Ahlén G, Koh S, Brass A, Peterson DL, Fons M, Milich DR, Hultgren C, Sällberg M.

J Infect Dis. 2010 Jun 15;201(12):1867-79. doi: 10.1086/652808.

PMID:
20446851
10.

Use of hepadnavirus core proteins as vaccine platforms.

Whitacre DC, Lee BO, Milich DR.

Expert Rev Vaccines. 2009 Nov;8(11):1565-73. doi: 10.1586/erv.09.121. Review.

11.

Interaction of the hepatitis B core antigen and the innate immune system.

Lee BO, Tucker A, Frelin L, Sallberg M, Jones J, Peters C, Hughes J, Whitacre D, Darsow B, Peterson DL, Milich DR.

J Immunol. 2009 Jun 1;182(11):6670-81. doi: 10.4049/jimmunol.0803683.

12.

A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection.

Frelin L, Wahlström T, Tucker AE, Jones J, Hughes J, Lee BO, Billaud JN, Peters C, Whitacre D, Peterson D, Milich DR.

J Virol. 2009 Feb;83(3):1379-92. doi: 10.1128/JVI.01902-08. Epub 2008 Nov 12.

13.

The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor alpha mediated liver disease.

Frelin L, Brenndörfer ED, Ahlén G, Weiland M, Hultgren C, Alheim M, Glaumann H, Rozell B, Milich DR, Bode JG, Sällberg M.

Gut. 2006 Oct;55(10):1475-83. Epub 2006 Mar 9.

14.

Relation between viral fitness and immune escape within the hepatitis C virus protease.

Söderholm J, Ahlén G, Kaul A, Frelin L, Alheim M, Barnfield C, Liljeström P, Weiland O, Milich DR, Bartenschlager R, Sällberg M.

Gut. 2006 Feb;55(2):266-74. Epub 2005 Aug 16.

15.

Immune tolerance split between hepatitis B virus precore and core proteins.

Chen M, Sällberg M, Hughes J, Jones J, Guidotti LG, Chisari FV, Billaud JN, Milich DR.

J Virol. 2005 Mar;79(5):3016-27.

16.

A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen.

Chen MT, Billaud JN, Sällberg M, Guidotti LG, Chisari FV, Jones J, Hughes J, Milich DR.

Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14913-8. Epub 2004 Oct 5.

17.

Immunogenetics of the response to HBsAg vaccination.

Milich DR, Leroux-Roels GG.

Autoimmun Rev. 2003 Sep;2(5):248-57. Review.

PMID:
12965175
18.

A malaria vaccine candidate based on a hepatitis B virus core platform.

Sällberg M, Hughes J, Jones J, Phillips TR, Milich DR.

Intervirology. 2002;45(4-6):350-61.

PMID:
12602355
19.

Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent.

Lazdina U, Alheim M, Nyström J, Hultgren C, Borisova G, Sominskaya I, Pumpens P, Peterson DL, Milich DR, Sällberg M.

J Gen Virol. 2003 Jan;84(Pt 1):139-46.

PMID:
12533710
20.

Influence of C4A deficiency on nonresponse to HBsAg vaccination: a new immune response gene.

Milich DR.

J Hepatol. 2002 Sep;37(3):396-9. Review. No abstract available.

PMID:
12175637
21.

Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate.

Milich DR, Hughes J, Jones J, Sällberg M, Phillips TR.

Vaccine. 2001 Dec 12;20(5-6):771-88.

PMID:
11738741
23.

Modeling the T-helper cell response in acute and chronic hepatitis B virus infection using T-cell receptor transgenic mice.

Chen M, Sällberg M, Thung SN, Hughes J, Jones J, Milich DR.

Antiviral Res. 2001 Nov;52(2):99-111.

PMID:
11672819
24.

Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells.

Lazdina U, Cao T, Steinbergs J, Alheim M, Pumpens P, Peterson DL, Milich DR, Leroux-Roels G, Sällberg M.

J Virol. 2001 Jul;75(14):6367-74.

25.

Hepatitis B virus core antigen binds and activates naive human B cells in vivo: studies with a human PBL-NOD/SCID mouse model.

Cao T, Lazdina U, Desombere I, Vanlandschoot P, Milich DR, Sällberg M, Leroux-Roels G.

J Virol. 2001 Jul;75(14):6359-66.

26.

Humoral and CD4(+) T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein.

Lazdina U, Hultgren C, Frelin L, Chen M, Lodin K, Weiland O, Leroux-Roels G, Quiroga JA, Peterson DL, Milich DR, Sällberg M.

J Gen Virol. 2001 Jun;82(Pt 6):1299-308.

PMID:
11369873
27.

Transgenic technology and the study of hepatitis viruses: a review of what we have learned.

Milich DR.

Can J Gastroenterol. 2000 Oct;14(9):781-7. Review.

PMID:
11064315
28.

Emergence of the precore mutant late in chronic hepatitis B infection correlates with the severity of liver injury and mutations in the core region.

Maruyama T, Mitsui H, Maekawa H, Yamada H, Hirayama M, Iino S, Yasuda K, Koike K, Kimura S, Milich DR.

Am J Gastroenterol. 2000 Oct;95(10):2894-904.

PMID:
11051365
29.

Nondeletional T-cell receptor transgenic mice: model for the CD4(+) T-cell repertoire in chronic hepatitis B virus infection.

Chen M, Sällberg M, Thung SN, Hughes J, Jones J, Milich DR.

J Virol. 2000 Aug;74(16):7587-99.

30.
31.

Do T cells "see" the hepatitis B core and e antigens differently?

Milich DR.

Gastroenterology. 1999 Mar;116(3):765-8. Review. No abstract available.

PMID:
10029635
32.

Limited humoral immunity in hepatitis C virus infection.

Chen M, Sällberg M, Sönnerborg A, Weiland O, Mattsson L, Jin L, Birkett A, Peterson D, Milich DR.

Gastroenterology. 1999 Jan;116(1):135-43.

PMID:
9869611
33.

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses.

Hultgren C, Milich DR, Weiland O, Sällberg M.

J Gen Virol. 1998 Oct;79 ( Pt 10):2381-91.

PMID:
9780043
34.

Human and murine antibody recognition is focused on the ATPase/helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein.

Chen M, Sällberg M, Sönnerborg A, Jin L, Birkett A, Peterson D, Weiland O, Milich DR.

Hepatology. 1998 Jul;28(1):219-24.

PMID:
9657115
35.
36.

Role of B cells in antigen presentation of the hepatitis B core.

Milich DR, Chen M, Schödel F, Peterson DL, Jones JE, Hughes JL.

Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14648-53.

37.

Precore wild-type DNA and immune complexes persist in chronic hepatitis B after seroconversion: no association between genome conversion and seroconversion.

Maruyama T, Kuwata S, Koike K, Iino S, Yasuda K, Yotsuyanagi H, Moriya K, Maekawa H, Yamada H, Shibata Y, Milich DR.

Hepatology. 1998 Jan;27(1):245-53.

PMID:
9425944
38.
40.
41.

Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy.

Zhang ZX, Milich DR, Peterson DL, Birkett A, Schvarcz R, Weiland O, Sällberg M.

J Infect Dis. 1997 Jun;175(6):1294-301.

PMID:
9180166
42.

Characterization of CD8+ cytotoxic T-lymphocyte responses after genetic immunization with retrovirus vectors expressing different forms of the hepatitis B virus core and e antigens.

Townsend K, Sällberg M, O'Dea J, Banks T, Driver D, Sauter S, Chang SM, Jolly DJ, Mento SJ, Milich DR, Lee WT.

J Virol. 1997 May;71(5):3365-74.

43.

The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype.

Milich DR, Schödel F, Hughes JL, Jones JE, Peterson DL.

J Virol. 1997 Mar;71(3):2192-201.

44.

Immunization with hybrid hepatitis B virus core particles carrying circumsporozoite antigen epitopes protects mice against Plasmodium yoelii challenge.

Schödel F, Peterson D, Milich DR, Charoenvit Y, Sadoff J, Wirtz R.

Behring Inst Mitt. 1997 Feb;(98):114-9.

PMID:
9382731
45.
46.

Pathobiology of acute and chronic hepatitis B virus infection: an introduction.

Milich DR.

J Viral Hepat. 1997;4 Suppl 2:25-30. Review. No abstract available.

PMID:
9429207
47.

Immunogenicity and antigenicity of the ATPase/helicase domain of the hepatitis C virus non-structural 3 protein.

Sällberg M, Zhang ZX, Chen M, Jin L, Birkett A, Peterson DL, Milich DR.

J Gen Virol. 1996 Nov;77 ( Pt 11):2721-8.

PMID:
8922465
48.

Interleukin 12 suppresses autoantibody production by reversing helper T-cell phenotype in hepatitis B e antigen transgenic mice.

Milich DR, Wolf SF, Hughes JL, Jones JE.

Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6847-51.

49.

Characterization of self-reactive T cells that evade tolerance in hepatitis B e antigen transgenic mice.

Milich DR, Schödel F, Peterson DL, Jones JE, Hughes JL.

Eur J Immunol. 1995 Jun;25(6):1663-72.

PMID:
7542199
50.

The hepatitis nucleocapsid as a vaccine carrier moiety.

Milich DR, Peterson DL, Zheng J, Hughes JL, Wirtz R, Schödel F.

Ann N Y Acad Sci. 1995 May 31;754:187-201.

PMID:
7542855

Supplemental Content

Loading ...
Support Center